NCT02551068Completed
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib
High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 78 (actual)
- First submitted
- 1 Sept 2015
- Start date
- Dec 2015
- Primary completion date
- Aug 2025
- Lead sponsor
- University of British Columbia
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT02551068
What you commit to
- Study type: Interventional
- Participants enrolled: 78
- From Dec 2015 to the primary completion date, Aug 2025
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to treatment with nintedanib (based on Canadian labeling)
- Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program
Other illness
- Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)
- Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
Other
- Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%
- Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit
- Use of pirfenidone within 4 weeks of screening
- Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70)
Who the study is looking for
- Age 19 years or older
- Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria
- Appropriate candidate for pulmonary rehabilitation
- prescribed nintedanib by their treating physician or currently on nintedanib
- 6 minute walk distance 50m or more
- Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air
- Clinically stable for the preceding 6 weeks
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Of Calgary Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| McMaster University Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| UBC Okanagan Coordinator of this site? Confirm its status | Kelowna | Canada | Unknown status |
| Queens University Coordinator of this site? Confirm its status | Kingston | Canada | Unknown status |
| McGill University Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| Laval University Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| St. Paul's Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.